WO1999043850A1 - Method for the non-specific amplification of nucleic acid - Google Patents

Method for the non-specific amplification of nucleic acid Download PDF

Info

Publication number
WO1999043850A1
WO1999043850A1 PCT/EP1999/000332 EP9900332W WO9943850A1 WO 1999043850 A1 WO1999043850 A1 WO 1999043850A1 EP 9900332 W EP9900332 W EP 9900332W WO 9943850 A1 WO9943850 A1 WO 9943850A1
Authority
WO
WIPO (PCT)
Prior art keywords
rna
enzyme
sequence
rna polymerase
activity
Prior art date
Application number
PCT/EP1999/000332
Other languages
French (fr)
Inventor
B. Van Gemen
Original Assignee
Pamgene B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pamgene B.V. filed Critical Pamgene B.V.
Priority to JP2000533589A priority Critical patent/JP3641206B2/en
Priority to DE69900592T priority patent/DE69900592T2/en
Priority to AU25189/99A priority patent/AU748847B2/en
Priority to DK99904801T priority patent/DK1056884T3/en
Priority to AT99904801T priority patent/ATE210736T1/en
Priority to CA002322073A priority patent/CA2322073C/en
Priority to EP99904801A priority patent/EP1056884B9/en
Priority to US09/623,054 priority patent/US6338954B1/en
Publication of WO1999043850A1 publication Critical patent/WO1999043850A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates

Definitions

  • the present invention is concerned with a method for generating, in a non specific manner, multiple copies of RNA from a pool of mRNA's. Such a method is of particular importance in techniques for screening the differences in expression in given cell types or in cells under specific conditions.
  • each cell contains about 100,000 genes.
  • Gene expression varies between different cell types and between different stages of development of a given cell and is crucial to all biological processes, such as aging, ceil differentiation, and infectious or other disease states.
  • identification of genes that are differentially expressed in ceils under different conditions is of pnme interest in cellular biology.
  • Liang and Pardee Science, Vol 257, 967-971 , 1992; US 5,262,311 which issued on Nov. 16, 1993.
  • mRNA is first transcribed into cDNA and amplified using the Polymerase Chain Reaction (PCR).
  • PCR Polymerase Chain Reaction
  • a set of oligonucleotide pnmers is used, the first of which is anchored to the polyadenylated tail of a subset of mRNA's, the other being short and arbitrary in sequence so that it anneals at different positions relative to the first primer.
  • the method is used with different pairs of alterable sequences aiming at the amplification of as many mRNA's as possible from the ceils under investigation.
  • PCR products are labeled using tracer amounts of labeled (radioactive) nucleotides.
  • mRNA in a single cell can be characte ⁇ zed by 2 microinjecting into a cell a first amplification oligonucleotide comprising oligo-dT and the sequence of a bacteriophage promoter such as T7, T3 or SP6, reverse transcriptase and nucleotides to synthesize a first strand of cDNA from the mRNA in the cell. From the first strand of cDNA double stranded cDNA is synthesized.
  • this double stranded cDNA includes a functional promoter aRNA (anti-sense RNA) can now be synthesized therefrom using an RNA polymerase.
  • the aRNA is now re- amplified using random hexanucleotide primers with a reverse transcriptase to form first strand cDNA.
  • cDNA is made starting with a primer using the mRNA as a template.
  • the enzyme that is used for this reaction (reverse transcriptase) is hampered in the cDNA synthesis by structures in the mRNA.
  • the prior art methods are selective for mRNA's with little or no structure. This effect is further enhanced if the synthesized cDNA is amplified further, for instance by PCR. Due to the aforementioned it is common practice to use a large sample amount in these type of expression profiling analysis. Thus this technical threshold does not allow the analysis of only a few cells isolated on a cell sorter or a few cells isolated via micro dissection from a glass slide after microscope identification and selection.
  • the solution to the problem is the use of a non-selective poly A mRNA labeling and amplification method, i.e. a method not encompassing cDNA synthesis.
  • the present invention provides such a method.
  • the present invention is directed to a method for amplifying RNA by creating, in a non specific manner, multiple RNA copies starting from nucleic acid containing starting material comprising a pool of mRNA's each mRNA comprising a poly-A tail, wherein the material is contacted simultaneously with an oligonucleotide comprising an oligo-dT sequence, the sequence of a promoter recognized by a RNA polymerase and a transcription initiation region which is located between the oligo-dT sequence and the sequence of the promoter, and further with an enzyme having reverse transcriptase activity, an enzyme having RNase H activity and an enzyme having RNA polymerase activity and the necessary nucleotides and the resulting reaction mixture is maintained under the appropriate conditions for a sufficient amount of time for the enzymatic processes to take place.
  • the method of the present invention does not involve the production of cDNA intermediates; RNA is copied directly from the mRNA present in the material under investigation.
  • the method of the present invention does not need a cDNA as a basis for the amplification of the RNA.
  • the RNA is synthesized by an RNA polymerase, directly from the mRNA template. The activity of the RNA polymerase is independent from any secondary structures present in the mRNA and thus there are no differences in the way the different mRNA's are amplified depending on structures in the mRNA's.
  • the copies made represent the original mRNA population as present in the starting material. 3
  • the oligonucleotides used with the method of the invention comprise an oligo-dT sequence which will hybridize to the poly-andenylated tail at the 3' end of the mRNA's.
  • the oligonucleotides further comprise the sequence of a promoter recognized by an RNA polymerase and a transcription initiation region which is located between the oligo-dT sequence and the sequence of the promoter.
  • the promoter may be the promoter for any suitable RNA polymerase.
  • RNA polymerases are polymerases from E. coli and bacteriophages T7, T3 and SP6.
  • the RNA polymerase is a bacteriophage-derived RNA polymerase, in particular the T7 polymerase.
  • the oligonucleotide may be blocked at its 3' end. If the oligonucleotide is not blocked at its 3' end, it is extendible by the reverse transcriptase. However, the cDNA that would thus be generated will not be a part of the amplification mechanism (as it is with prior art methods). It even interferes with the other enzymatic reactions.
  • the extension of the oligonucleotide is only with a very limited number of nucleotides because if the promoter is made double stranded the transcription on the mRNA template by the RNA polymerase will start immediately. This transcription will "push" the RT from the RNA template and extension (i.e.
  • cDNA synthesis of the oligonucleotide can no longer occur.
  • the oligonucleotide can be blocked at its 3' end to prevent any extension therefrom by the reverse transcriptase along the RNA template;, the reverse transcriptase will not be able to start extension of the 3' end of the oligonucleotide and no cDNA is synthesized.
  • the reverse transcriptase does synthesize a complementary strand of the promoter sequence present in the template.
  • the use of the oligonucleotide is depicted schematically in figure 1. Upon hybridization of the oligonucleotide the poly-A sequence of the mRNA is cut by an enzyme having RNase H activity.
  • This activity may be the RNase H activity of the reverse transcriptase or the RNaseH activity of a separate enzyme like, for example, E.coli RNaseH, or both.
  • preferred transcriptases used with the method of the invention are transcriptases having RNaseH activity, such as AMV-RT or MMLV-RT.
  • the newly generated 3' end of the RNA is extended on the oligonucleotide template to generate a double stranded promoter sequence.
  • new RNA copies of the original mRNA are made.
  • labels may be incorporated and typically 100-1000 copies of each RNA are being made.
  • the copies made are antisense RNA and thus comprise a poly-T stretch at the 5' end.
  • RNA polymerase normally uses a double stranded template for the transcription the enzymes is not likely to be hampered by structures in the mRNA. Furthermore, the processivity of, for example, the T7 RNA polymerase is very high, usually more than 250 nucleotides per second on a DNA template. This means that the amplification rate is determined by the number of initiation events per promoter, per time unit. Since the promoter is identical for each mRNA there is no selectivity in the amplification. 4 The conditions under which the reactions should be performed are the normal conditions, i.e. buffer constitutions and temperatures, known to be optimal for the mix of enzymes used.
  • RNA may need to be amplified further without introducing selectivity, thus again avoiding i.e. cDNA synthesis.
  • selectivity thus again avoiding i.e. cDNA synthesis.
  • RNA may now be further amplified by the following method.
  • RNA ligase To the 3' end of every RNA molecule a double stranded promoter sequence is ligated by using RNA ligase. Since all 3' ends are chemically identical there is no selectivity.
  • the ligated promoter is used to initiate a second round of transcription generating more (labeled) RNA. This is illustrated in figure 2.
  • the generated RNA copies made as described above are contacted with an RNA ligase, a double stranded nucleic acid complex comprising a double stranded DNA promoter sequence that can be recognized by a RNA polymerase, whereby one strand of said complex has a stretch of RNA attached to the 5' end of one of the DNA strands, an enzyme having RNA polymerase activity, and the necessary nucleotides.
  • the resulting reaction mixture is maintained under the appropriate conditions for a sufficient amount of time for the amplification to take place
  • RNA template is used to generate new sense strand RNA molecules. Typically 100-1000 copies of each RNA is being made in the transcription reaction by the RNA polymerase.
  • the stretch of RNA attached to the 5' end of one of the DNA strands is phosphorylated at the 5' end. Phosporylation enables the 5' end to be ligated.
  • the promoter may be the same as in the first part of the procedure for example, the T7-promoter sequence may be used and the RNA polymerase than is T7 RNA polymerase.
  • the procedure wherein the ligase is used may be performed as a separate reaction. That is, after RNA copies have been generated in a procedure like the one depicted in figure 1 , the RNA copies may be transferred to another reaction medium and subjected to the second reaction.
  • Another elegant method to further enhance the amplification factor of the non-biased mRNA amplification method is by adding a poly A nucleotide stretch to the 3' end of the newly synthesized RNA.
  • the poly nucleotide stretch is added by the enzyme poly A polymerase. To this added poly A sequence the oligonucleotide, encompassing an oligo T stretch and T7 promoter can hybridize again and the previously described process may take place again.
  • RNA will be made by the transcription process and this newly synthesized RNA will be identical (for the large part) to the original mRNA that the whole reaction started with in the first place.
  • oligonucleotide encompassing an oligo T stretch and T7 promoter can also hybridize again to this RNA and now the process has entered in a continuous process of RNA synthesis by transcription, oligonucleotide annealing and double strand promoter synthesis.
  • the generated RNA copies made as described before in the basic method are contacted with a poly A polymerase, an oligonucleotide, encompassing an oligo T stretch and T7 promoter, a reverse transcriptase, a RNase H, a RNA polymerase and the necessary nucleotides.
  • the resulting reaction mixture is maintained under appropriate conditions for a sufficient amount of time for the amplification to take place.
  • one or more nucleotides used may be labeled.
  • RNA polymerase Due to the position of the newly added poly A stretch (3' end of the RNA molecules) the RNA polymerase will generate RNA of the opposite polarity.
  • the oligonucleotide, encompassing an oligo T stretch and T7 promoter may be the same as in the first part of the procedure.
  • the procedure in which the poly A polymerase is added may be performed as a separate reaction. That is, after RNA copies have been made in a procedure like the one depicted in figure 1 , the RNA copies may be transferred to another reaction medium and subjected to the reaction with poly A polymerase. Starting a continuous amplification process. When the poly A polymerase is added to the initial reaction mixture the continuous amplification process may even start immediately from the original mRNA template.
  • Figure 1 Schematic presentation of non-selective poly A mRNA amplification based on transcription. RNase H activity necessary for cutting the RNA can be associated with the AMV-RT.
  • Figure 2 Schematic presentation of the second round of non-selective amplification of the RNA products resulting from the first described non-selective amplification scheme (such as the one depicted in figure 1 ).
  • Figure 3 Silver stained Cleangei analysis of Tyras reactions using different dilutions of in vitro cribed RNA form example 1 as template. 1) 50 x dilution 2) 100 x dilution
  • Figure 4 Autoradiograph of Cleangei showing the radiolabeled Tyras amplification products.
  • Lane 1 input poly A+ RNA; lane 2, 5 minute labeling; lane 3, 10 minute labeling; lane 4, 20 minute labeling; lane 5, no template reaction; lane M, non-labeled marker.
  • FIG. 7 Silverstained Cleangei analysis of Tyras reactions using the poly A polymerase added poly A tail as target for hybridization of the T stretch encompassing oligonucleotide.
  • Lane 1 Tyras reaction using 5 microliter of reaction A as input: lane 2, Tyras reaction using 5 microliter of reaction B as input; lane 3 and lane 4, negative control lanes; M is marker lane.
  • the arrow indicates the position of the specific amplification product.
  • the method used in the examples is an embodiment of the method of the invention and referred to in the examples as "Tyras".
  • the method referred to as Tyras comprises the hybridization of an oligonucleotide, encompassing an oligo T stretch, to the poly A tail of the mRNA followed by RNase H digestion opposite the oligonucleotide and extension of the newly formed 3' end of the mRNA with reverse transcriptase.
  • the T7 RNA polymerase recognition sequence i.e. T7 promoter
  • the 7 original mRNA molecules are transcribed in multiple RNA copies of the opposite polarity (see figure 1).
  • Plasmid pG3O containing part of the genomic hepatitis B virus (HBV) sequence (nucleotide numbers 1662-1914, reference: Lai.M.E et al. (1991). Sequence analysis of hepatitis B virus genome of a new mutant of ayw subtype isolated in Sardinia Nucleic Acids Res. 19 (18), 5078) cloned in the Eco Rl site behind the T7 promoter was used to generate in vitro transcribed RNA containing a poly A stretch (25 nts) adjacent to the HBV sequence (nucleotide numbers 1662-1914).
  • the plasmid pG3O was digested with restriction enzyme Hind III according to a standard protocol as known by persons skilled in the art.
  • the length of the in vitro transcribed RNA is 306 nucleotides.
  • the in vitro transcribed RNA was DNase I treated (1 ⁇ l, 10 units) for 30 minutes at 37°C. Following the DNase I treatment the in vitro transcribed RNA was phenol/chloroform purified and ethanol precipitated with standard protocols known to persons skilled in the art. The pelleted in vitro transcribed RNA was dissolved in 20 ⁇ l water and dilutions in water used for subsequent experiments.
  • the in vitro transcribed RNA (APPROXIMATELY 1 ⁇ g/ ⁇ l) generated in example 1 was used as template to generate new RNA in a Tyras reaction.
  • the in vitro transcribed RNA from example 1 was diluted 50, 100, 500 and 1000 times, respectively, in water.
  • the Tyras reactions contained: 2 ⁇ l water, 4 ⁇ l 5x NN buffer (Tris-HCI 200 mM, pH 8.5, MgCI2 60 mM, KCL 350 mM, DTT 25 mM, dNTP's 5 mM each, rATP 10mM, rUTP 10mM, rCTP 10mM, rGTP 7.5 mM, ITP 2.5 mM), 4 ⁇ l primer mix (76.9 ⁇ l 100% DMSO, 11.6 ⁇ l oligonucleotide PH26 [42.9 ⁇ M, sequence 5' AAT TCT AAT ACG ACT CAC TAT AGG GAG AGA AGG ATA CCA CTA GCT AGC 8
  • the Tyras reaction was used to generate 32 P radiolabeled RNA from human placenta poly A+ RNA template.
  • the Tyras reaction contained 4 ⁇ l 5x NN* buffer (Tris-HCI 200 mM, pH 8.5, MgCI2 60 mM, KCL 350 mM, DTT 25 mM, dNTP's 5 mM each, rGTP 10mM, rUTP 10mM, rCTP 10mM), 4 ⁇ l primer mix PH26 (see example 2), 6.5 ⁇ l ⁇ - 3 P-ATP and 0.5 ⁇ l human poly A+ RNA (1 ⁇ g/ ⁇ l, Clontech lot NR. 7050106, Cat.6518-1).
  • the ingredients were mixed tapping the tube and incubated at 65°C for 5 minutes and subsequently at 41 °C for 5 minutes.
  • Than 5 ⁇ l enzyme mix (sorbitol 1.5M, BSA 2.1 ⁇ g, RNase H 0.08 units, T7 RNA polymerase 32 units and AMV-Reverse Transcriptase 25.3 units) was added to the reaction and gently mixed by tapping the tube. After a short incubation of 5 minutes 41 °C the tubes were briefly spun in centrifuge to collect all the droplets on the bottom of the tube.
  • 0.4 ⁇ l rATP 100 mM was added after 0, 5 and 15 minutes incubation at 41 °C, respectively. After the addition of the rATP the reactions were incubated for 90 minutes at 41 °C. After the reaction the tubes were stored at -20°C.
  • the Tyras reactions of example 3 were pooled and used to interrogate a filter probe array.
  • the composition of the probe array is shown in table 1 , the oligonucleotides were spotted on a zeta-probe membrane (BioRad Laboratories, 2000 Alfred Nobel Drive, Hercules, CA 94547, USA).
  • the pooled Tyras reactions from example 3, in total 58.5 ⁇ l were added to 25 ml hybridization mix (5x SSC [20x SSC is NaCI 3M, Na-citrate0.3M], 7% SDS, 20 mM NaPi, 10x Denhardts [100x Denhardts is Polyvinylpyrolidone 2%, BSA 2% and Ficol 2%]).
  • the filter with the probe array was incubated in the hybridization mix for 16 hours (O/N) in a shaking incubator at 42°C.
  • the probe array filter was washed two times in 3x SSC/1 % SDS for 7 minutes at room temperature. After the washes the damp filter was wrapped in foil and exposed to an X-ray film O/N at -70°C. The result of the exposure is shown in figure 3.
  • the autoradiograph clearly shows a positive signal at the position of the G3PDH probe OT1446 on the array.
  • the Tyras reaction was used to generate 32 P radiolabeled RNA from human poly A+ RNA template.
  • the Tyras reaction contained 4 ⁇ l 5x NN* buffer (Tris- HCI 200 mM, pH 8.5, MgCI2 60 mM, KCL 350 mM, DTT 25 mM, dNTP's 5 mM each, rGTP 10mM, rUTP 10mM, rCTP 10mM), 4 ⁇ l primer mix PH26 (see example 2), 6.5 ⁇ l ⁇ - 32 P-ATP (reactions A and B) or 5.5 ⁇ l ⁇ - 32 P-ATP (reactions D, E and C) and 0.5 ⁇ l human poly A+ RNA (Clontech lot NR.
  • 4 ⁇ l 5x NN* buffer Tris- HCI 200 mM, pH 8.5, MgCI2 60 mM, KCL 350 mM, DTT 25 mM, dNTP's 5 m
  • reaction C only water was added since this was the negative control.
  • the ingredients were mixed by pipetting up and down 5 times and incubated at 65°C for 5 minutes and subsequently at 41°C for 5 minutes.
  • Than 5 ⁇ l enzyme mix (sorbitol 1.5M, BSA 2.1 ⁇ g, RNase H 0.08 units, T7 RNA polymerase 32units and AMV-Reverse Transcriptase 25.3 units) was added to the reaction and gently mixed by tapping the tube.
  • D and E 1 ⁇ l of T7 mix 31 units T7 RNA polymerase and 0.6 units RNase H was 10 added and gently mixed by tapping the tube.
  • the filter with the "E quadrant" of an Atlas Human cDNA Expression Array was incubated in hybridization mix (see example 4) for 15 minutes at 50°C.
  • the pooled reactions A, B and D were added to the hybridization mix on the filter and further incubated for 16 hours (O/N).
  • the filter with "E quadrant” of an Atlas Human cDNA Expression Array was washed 4 times with 3x SSC/1 % SDS at room temperature.
  • the damp filter was wrapped in foil and exposed to an X-ray film at -70°C for 65 hours. The result is depicted in figure 4 below and clearly shows positive spots on the array indicating good labeling of the poly A+ RNA with the Tyras method.
  • the reactions were incubated at 37°C for 20 minutes (reaction A) or 60 minutes (reaction B).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention is concerned with a method for generating, in a non specific manner, multiple copies of RNA from a pool of mRNA's. Such a method is of particular importance in techniques for screening the differences in expression in given cell types or in cells under specific conditions. The present invention provides a non-selective poly A mRNA labeling and amplification method, i.e. a method not encompassing cDNA synthesis. The present invention is directed to a method for amplifying RNA by creating, in a non specific manner, multiple RNA copies starting from nucleic acid containing starting material comprising a pool of mRNA's each mRNA comprising a poly-A tail, wherein the material is contacted simultaneously with an oligonucleotide comprising an oligo-dT sequence, the sequence of a promoter recognized by an RNA polymerase and a transcription initiation region which is located between the oligo-dT sequence and the sequence of the promoter, and further with an enzyme having reverse transcriptase activity, an enzyme having RNase H activity and an enzyme having RNA polymerase activity and the necessary nucleotides and the resulting reaction mixture is maintained under the appropriate conditions for a sufficient amount of time for the enzymatic processes to take place. In a preferred method of the invention the generated RNA copies made are contacted with an RNA ligase, a double stranded nucleic acid complex comprising a double stranded DNA promoter sequence that can be recognized by an RNA polymerase, whereby one strand of said complex has a stretch of RNA attached to the 5' end of one of the DNA strands, an enzyme having RNA polymerase activity, and the necessary nucleotides. The resulting reaction mixture is maintained under the appropriate conditions for a sufficient amount of time for the amplification to take place.

Description

Method for the non-specific amplification of nucleic acid.
The present invention is concerned with a method for generating, in a non specific manner, multiple copies of RNA from a pool of mRNA's. Such a method is of particular importance in techniques for screening the differences in expression in given cell types or in cells under specific conditions.
In cells of higher organisms only some 15% of the genes present (each cell contains about 100,000 genes) is expressed. Gene expression varies between different cell types and between different stages of development of a given cell and is crucial to all biological processes, such as aging, ceil differentiation, and infectious or other disease states. Thus the identification of genes that are differentially expressed in ceils under different conditions is of pnme interest in cellular biology.
To be able to analyze the mRNA content derived from only a few cells a method is needed to amplify the mRNA present in the cell(s) under investigation. Much effort has already been put in methods to examine the mRNA population of a cell. This has lead to the development of techniques to label nucleic acid material starting from the mRNA population of a cell aimed at the identification of genes that are differentially expressed in cells under various conditions.
One method for screening differences in gene expression is a method known as Differential Display (Liang and Pardee, Science, Vol 257, 967-971 , 1992; US 5,262,311 which issued on Nov. 16, 1993). With the method of Liang and Pardee mRNA is first transcribed into cDNA and amplified using the Polymerase Chain Reaction (PCR). A set of oligonucleotide pnmers is used, the first of which is anchored to the polyadenylated tail of a subset of mRNA's, the other being short and arbitrary in sequence so that it anneals at different positions relative to the first primer. The method is used with different pairs of alterable sequences aiming at the amplification of as many mRNA's as possible from the ceils under investigation. The
PCR products are labeled using tracer amounts of labeled (radioactive) nucleotides.
An improvement on the Differential Display method of Liang and Pardee was disclosed in US 5,589,726. The method described in US 5,589,726 differs from the method of Liang and Pardee in that it uses longer primers (22-30 nucleotides compared to the 9-14 base pnmers originally described by Liang and Pardee).
Another alleged improvement over the Differential Display technique as oπginally disclosed by Liang and Pardee is disclosed in WO 97/37045. In this application a method is disclosed that, again, is based on PCR: This method uses an oligo-dT pπmer rather than an anchored pπmer. Thus, after the reverse transcription step only one cDNA population coveπng all possible mRNA sequences is created. The cDNA thus obtained is titrated into the PCR process by running several PCR reactions at decreasing concentrations of cDNA. This serves to calibrate the method and to protect it against false negatives. The PCR reaction may be performed with anchored pnmers again.
Yet another method for "expression profiling" of mRNA's is disclosed in US 5,514,545. With this method mRNA in a single cell can be characteπzed by 2 microinjecting into a cell a first amplification oligonucleotide comprising oligo-dT and the sequence of a bacteriophage promoter such as T7, T3 or SP6, reverse transcriptase and nucleotides to synthesize a first strand of cDNA from the mRNA in the cell. From the first strand of cDNA double stranded cDNA is synthesized. Since this double stranded cDNA includes a functional promoter aRNA (anti-sense RNA) can now be synthesized therefrom using an RNA polymerase. The aRNA is now re- amplified using random hexanucleotide primers with a reverse transcriptase to form first strand cDNA.
With all the above techniques cDNA is made starting with a primer using the mRNA as a template. However, the enzyme that is used for this reaction (reverse transcriptase) is hampered in the cDNA synthesis by structures in the mRNA. As a result the prior art methods are selective for mRNA's with little or no structure. This effect is further enhanced if the synthesized cDNA is amplified further, for instance by PCR. Due to the aforementioned it is common practice to use a large sample amount in these type of expression profiling analysis. Thus this technical threshold does not allow the analysis of only a few cells isolated on a cell sorter or a few cells isolated via micro dissection from a glass slide after microscope identification and selection.
The solution to the problem is the use of a non-selective poly A mRNA labeling and amplification method, i.e. a method not encompassing cDNA synthesis.
The present invention provides such a method. The present invention is directed to a method for amplifying RNA by creating, in a non specific manner, multiple RNA copies starting from nucleic acid containing starting material comprising a pool of mRNA's each mRNA comprising a poly-A tail, wherein the material is contacted simultaneously with an oligonucleotide comprising an oligo-dT sequence, the sequence of a promoter recognized by a RNA polymerase and a transcription initiation region which is located between the oligo-dT sequence and the sequence of the promoter, and further with an enzyme having reverse transcriptase activity, an enzyme having RNase H activity and an enzyme having RNA polymerase activity and the necessary nucleotides and the resulting reaction mixture is maintained under the appropriate conditions for a sufficient amount of time for the enzymatic processes to take place.
This will lead to the formation of multiple anti-sense RNA copies of the mRNA's present in the reaction mixture. The method of the present invention does not involve the production of cDNA intermediates; RNA is copied directly from the mRNA present in the material under investigation. The method of the present invention does not need a cDNA as a basis for the amplification of the RNA. The RNA is synthesized by an RNA polymerase, directly from the mRNA template. The activity of the RNA polymerase is independent from any secondary structures present in the mRNA and thus there are no differences in the way the different mRNA's are amplified depending on structures in the mRNA's. The copies made represent the original mRNA population as present in the starting material. 3
The oligonucleotides used with the method of the invention comprise an oligo-dT sequence which will hybridize to the poly-andenylated tail at the 3' end of the mRNA's. The oligonucleotides further comprise the sequence of a promoter recognized by an RNA polymerase and a transcription initiation region which is located between the oligo-dT sequence and the sequence of the promoter. The promoter may be the promoter for any suitable RNA polymerase. Examples of RNA polymerases are polymerases from E. coli and bacteriophages T7, T3 and SP6. Preferably the RNA polymerase is a bacteriophage-derived RNA polymerase, in particular the T7 polymerase. The oligonucleotide may be blocked at its 3' end. If the oligonucleotide is not blocked at its 3' end, it is extendible by the reverse transcriptase. However, the cDNA that would thus be generated will not be a part of the amplification mechanism (as it is with prior art methods). It even interferes with the other enzymatic reactions. The extension of the oligonucleotide is only with a very limited number of nucleotides because if the promoter is made double stranded the transcription on the mRNA template by the RNA polymerase will start immediately. This transcription will "push" the RT from the RNA template and extension (i.e. cDNA synthesis) of the oligonucleotide can no longer occur. The oligonucleotide can be blocked at its 3' end to prevent any extension therefrom by the reverse transcriptase along the RNA template;, the reverse transcriptase will not be able to start extension of the 3' end of the oligonucleotide and no cDNA is synthesized. The reverse transcriptase does synthesize a complementary strand of the promoter sequence present in the template. The use of the oligonucleotide is depicted schematically in figure 1. Upon hybridization of the oligonucleotide the poly-A sequence of the mRNA is cut by an enzyme having RNase H activity. This activity may be the RNase H activity of the reverse transcriptase or the RNaseH activity of a separate enzyme like, for example, E.coli RNaseH, or both. In that respect preferred transcriptases used with the method of the invention are transcriptases having RNaseH activity, such as AMV-RT or MMLV-RT. The newly generated 3' end of the RNA is extended on the oligonucleotide template to generate a double stranded promoter sequence. By application of the RNA polymerase new RNA copies of the original mRNA are made. During this transcription step labels may be incorporated and typically 100-1000 copies of each RNA are being made. The copies made are antisense RNA and thus comprise a poly-T stretch at the 5' end. Since the RNA polymerase normally uses a double stranded template for the transcription the enzymes is not likely to be hampered by structures in the mRNA. Furthermore, the processivity of, for example, the T7 RNA polymerase is very high, usually more than 250 nucleotides per second on a DNA template. This means that the amplification rate is determined by the number of initiation events per promoter, per time unit. Since the promoter is identical for each mRNA there is no selectivity in the amplification. 4 The conditions under which the reactions should be performed are the normal conditions, i.e. buffer constitutions and temperatures, known to be optimal for the mix of enzymes used.
If the interest exists to make an expression profile of just a few cells the above described amplification may not yield enough copies of the RNA, for example to generate a signal if the copies are labeled. In certain special cases the RNA may need to be amplified further without introducing selectivity, thus again avoiding i.e. cDNA synthesis. There are multiple solutions to this problem, all transcription based.
An elegant solution is depicted in figure 2. The newly synthesized RNA may now be further amplified by the following method. To the 3' end of every RNA molecule a double stranded promoter sequence is ligated by using RNA ligase. Since all 3' ends are chemically identical there is no selectivity. The ligated promoter is used to initiate a second round of transcription generating more (labeled) RNA. This is illustrated in figure 2. Thus in a preferred method of the invention the generated RNA copies made as described above are contacted with an RNA ligase, a double stranded nucleic acid complex comprising a double stranded DNA promoter sequence that can be recognized by a RNA polymerase, whereby one strand of said complex has a stretch of RNA attached to the 5' end of one of the DNA strands, an enzyme having RNA polymerase activity, and the necessary nucleotides. The resulting reaction mixture is maintained under the appropriate conditions for a sufficient amount of time for the amplification to take place
Again, one or more of the nucleotides used may be labeled. Due to the orientation of the RNA polymerase promoter sequence the RNA template is used to generate new sense strand RNA molecules. Typically 100-1000 copies of each RNA is being made in the transcription reaction by the RNA polymerase.
Preferably the stretch of RNA attached to the 5' end of one of the DNA strands is phosphorylated at the 5' end. Phosporylation enables the 5' end to be ligated. The promoter may be the same as in the first part of the procedure for example, the T7-promoter sequence may be used and the RNA polymerase than is T7 RNA polymerase.
Interestingly the sense RNA made in this second round of transcription contains again a poly A stretch at the 3' end making is possible to perform multiple cycles of amplification by repeatedly performing the method as illustrated by figure 1 and the method using the ligase as illustrated in figure 2.
The procedure wherein the ligase is used may be performed as a separate reaction. That is, after RNA copies have been generated in a procedure like the one depicted in figure 1 , the RNA copies may be transferred to another reaction medium and subjected to the second reaction.
When all enzymes and the oligonucleotide and the promoter construct are combined with the initial reaction mixture a continuous process may even be obtained. Another elegant method to further enhance the amplification factor of the non-biased mRNA amplification method is by adding a poly A nucleotide stretch to the 3' end of the newly synthesized RNA. The poly nucleotide stretch is added by the enzyme poly A polymerase. To this added poly A sequence the oligonucleotide, encompassing an oligo T stretch and T7 promoter can hybridize again and the previously described process may take place again. As a result again RNA will be made by the transcription process and this newly synthesized RNA will be identical (for the large part) to the original mRNA that the whole reaction started with in the first place. One skilled in the art understands that the oligonucleotide, encompassing an oligo T stretch and T7 promoter can also hybridize again to this RNA and now the process has entered in a continuous process of RNA synthesis by transcription, oligonucleotide annealing and double strand promoter synthesis. Thus in a preferred method of the invention the generated RNA copies made as described before in the basic method are contacted with a poly A polymerase, an oligonucleotide, encompassing an oligo T stretch and T7 promoter, a reverse transcriptase, a RNase H, a RNA polymerase and the necessary nucleotides. The resulting reaction mixture is maintained under appropriate conditions for a sufficient amount of time for the amplification to take place. In the mix one or more nucleotides used may be labeled.
Due to the position of the newly added poly A stretch (3' end of the RNA molecules) the RNA polymerase will generate RNA of the opposite polarity. The oligonucleotide, encompassing an oligo T stretch and T7 promoter may be the same as in the first part of the procedure. The procedure in which the poly A polymerase is added may be performed as a separate reaction. That is, after RNA copies have been made in a procedure like the one depicted in figure 1 , the RNA copies may be transferred to another reaction medium and subjected to the reaction with poly A polymerase. Starting a continuous amplification process. When the poly A polymerase is added to the initial reaction mixture the continuous amplification process may even start immediately from the original mRNA template.
BRIEF DESCRIPTION OF THE FIGURES:
Figure 1 : Schematic presentation of non-selective poly A mRNA amplification based on transcription. RNase H activity necessary for cutting the RNA can be associated with the AMV-RT.
Figure 2. Schematic presentation of the second round of non-selective amplification of the RNA products resulting from the first described non-selective amplification scheme (such as the one depicted in figure 1 ). Figure 3. Silver stained Cleangei analysis of Tyras reactions using different dilutions of in vitro cribed RNA form example 1 as template. 1) 50 x dilution 2) 100 x dilution
3) 500 x dilution
4) 1000 x dilution
5) no template
M) 100-400 nt marker i) input
Figure 4. Autoradiograph of Cleangei showing the radiolabeled Tyras amplification products. Lane 1 , input poly A+ RNA; lane 2, 5 minute labeling; lane 3, 10 minute labeling; lane 4, 20 minute labeling; lane 5, no template reaction; lane M, non-labeled marker.
Figure 5. Autoradiograph of the probe array filer described in table 1 interrogated with the Tyras reaction mixture of example 3.
Figure 6. Autoradiograph of the filter with the "E quadrant" of an Atlas Human cDNA Expression Array. The visible spots clearly indicate hybridization of labeled poly A+ RNA by Tyras. The arrow points to a control spot of G3PDH probe OT1446 that was also positive in example 4 (see figure 5).
Figure 7. Silverstained Cleangei analysis of Tyras reactions using the poly A polymerase added poly A tail as target for hybridization of the T stretch encompassing oligonucleotide.
Lane 1 , Tyras reaction using 5 microliter of reaction A as input: lane 2, Tyras reaction using 5 microliter of reaction B as input; lane 3 and lane 4, negative control lanes; M is marker lane. The arrow indicates the position of the specific amplification product.
EXAMPLES:
Introduction
The method used in the examples is an embodiment of the method of the invention and referred to in the examples as "Tyras". The method referred to as Tyras comprises the hybridization of an oligonucleotide, encompassing an oligo T stretch, to the poly A tail of the mRNA followed by RNase H digestion opposite the oligonucleotide and extension of the newly formed 3' end of the mRNA with reverse transcriptase. In this way the T7 RNA polymerase recognition sequence (i.e. T7 promoter) that is part of the oligonucleotide encompassing an oligo T stretch is made double stranded. Upon binding of the T7 RNA polymerase to the promoter the 7 original mRNA molecules are transcribed in multiple RNA copies of the opposite polarity (see figure 1).
Materials
Most enzymes, radiolabeled nucleotides, acrylamide Cleangels and oligonucleotides were purchased from Amersham Pharmacia, Bergrand 230, 4707 AT Roosendaal, The Netherlands. AMV-reverse transcriptase was purchased from Seikagaku, Rockville, MD 120248,USA. Human poly A+ RNA was purchase from ClonTech/Westburg, PO Box 214, 3830 AE Leiden, The Netherlands.
Example 1.
Plasmid pG3O containing part of the genomic hepatitis B virus (HBV) sequence (nucleotide numbers 1662-1914, reference: Lai.M.E et al. (1991). Sequence analysis of hepatitis B virus genome of a new mutant of ayw subtype isolated in Sardinia Nucleic Acids Res. 19 (18), 5078) cloned in the Eco Rl site behind the T7 promoter was used to generate in vitro transcribed RNA containing a poly A stretch (25 nts) adjacent to the HBV sequence (nucleotide numbers 1662-1914). The plasmid pG3O was digested with restriction enzyme Hind III according to a standard protocol as known by persons skilled in the art. The linearized plasmid was transcribed in a standard T7 RNA polymerase in vitro transcription reaction (composition: tris-HCI 40 mM, pH=7.5, MgCI2 6 mM, spermidine 2 mM, NaCI 10 mM, DTT 10 mM, rNTP's 0.5 mM each, RNA Guard 20 units and 46.5 units T7 RNA polymerase) for 3 hours at 37 °C. The length of the in vitro transcribed RNA is 306 nucleotides. The in vitro transcribed RNA was DNase I treated (1 μl, 10 units) for 30 minutes at 37°C. Following the DNase I treatment the in vitro transcribed RNA was phenol/chloroform purified and ethanol precipitated with standard protocols known to persons skilled in the art. The pelleted in vitro transcribed RNA was dissolved in 20 μl water and dilutions in water used for subsequent experiments.
Example 2
The in vitro transcribed RNA (APPROXIMATELY 1 μg/μl) generated in example 1 was used as template to generate new RNA in a Tyras reaction. The in vitro transcribed RNA from example 1 was diluted 50, 100, 500 and 1000 times, respectively, in water. The Tyras reactions contained: 2 μl water, 4 μl 5x NN buffer (Tris-HCI 200 mM, pH 8.5, MgCI2 60 mM, KCL 350 mM, DTT 25 mM, dNTP's 5 mM each, rATP 10mM, rUTP 10mM, rCTP 10mM, rGTP 7.5 mM, ITP 2.5 mM), 4 μl primer mix (76.9 μl 100% DMSO, 11.6 μl oligonucleotide PH26 [42.9μM, sequence 5' AAT TCT AAT ACG ACT CAC TAT AGG GAG AGA AGG ATA CCA CTA GCT AGC 8
GTT TTT TTT TTT TTT TTT TTT TTT 3'-biotine] and 11.5 μl water for total volume of 100 μl ) and 5 μl of the appropriate dilution of in vitro transcribed RNA from example 1. The reaction was incubated at 65°C for 5 minutes and subsequently at 41 °C for 5 minutes. Than 5 μl enzyme mix (sorbitol 1.5M, BSA 2.1 μg, RNase H 0.08 units, T7 RNA polymerase 32units and AMV-Reverse Transcriptase 25.3 units) was added to the reaction and gently mixed by tapping the tube. After a short incubation of 5 minutes 41 °C the tubes were briefly spun in a centrifuge to collect all the droplets on the bottom of the tube. The reactions were than incubated for 90 minutes at 41 °C. After the reaction the tubes were stored at -20°C. The reactions were analyzed on a 10% acrylamide Cleangei, 0.5 μl of the Tyras reaction was mixed with 7.5 μl formamide loading dye (Ambion, 2130 woodward St. #200, Austin, Texas 78744-1832, USA) and run on the Cleangei according to the manufacturers protocol. The result is depicted in figure 1.
Example 3
In this example the Tyras reaction was used to generate 32P radiolabeled RNA from human placenta poly A+ RNA template. The Tyras reaction contained 4 μl 5x NN* buffer (Tris-HCI 200 mM, pH 8.5, MgCI2 60 mM, KCL 350 mM, DTT 25 mM, dNTP's 5 mM each, rGTP 10mM, rUTP 10mM, rCTP 10mM), 4 μl primer mix PH26 (see example 2), 6.5 μl α-3 P-ATP and 0.5 μl human poly A+ RNA (1 μg/μl, Clontech lot NR. 7050106, Cat.6518-1). The ingredients were mixed tapping the tube and incubated at 65°C for 5 minutes and subsequently at 41 °C for 5 minutes. Than 5 μl enzyme mix (sorbitol 1.5M, BSA 2.1 μg, RNase H 0.08 units, T7 RNA polymerase 32 units and AMV-Reverse Transcriptase 25.3 units) was added to the reaction and gently mixed by tapping the tube. After a short incubation of 5 minutes 41 °C the tubes were briefly spun in centrifuge to collect all the droplets on the bottom of the tube. In three tubes labeled A, B and C , respectively, 0.4 μl rATP (100 mM) was added after 0, 5 and 15 minutes incubation at 41 °C, respectively. After the addition of the rATP the reactions were incubated for 90 minutes at 41 °C. After the reaction the tubes were stored at -20°C.
The reactions were analyzed on a 10% acrylamide Cleangei, 0.5 μl of the Tyras reaction was mixed with 7.5 μl formamide loading dye (Ambion) and run on the Cleangei according to the manufacturers protocol. The result is depicted in figure 2.
Example 4
The Tyras reactions of example 3 were pooled and used to interrogate a filter probe array. The composition of the probe array is shown in table 1 , the oligonucleotides were spotted on a zeta-probe membrane (BioRad Laboratories, 2000 Alfred Nobel Drive, Hercules, CA 94547, USA). The pooled Tyras reactions from example 3, in total 58.5 μl were added to 25 ml hybridization mix (5x SSC [20x SSC is NaCI 3M, Na-citrate0.3M], 7% SDS, 20 mM NaPi, 10x Denhardts [100x Denhardts is Polyvinylpyrolidone 2%, BSA 2% and Ficol 2%]). The filter with the probe array was incubated in the hybridization mix for 16 hours (O/N) in a shaking incubator at 42°C.
Table 1. Composition of the oligonucleotide probe array interrogated with the labeled Tyras reacϋons of example 3. gamma-actin gamma-actin gamma-actin gamma-actin
(+)probe:OT858 (+)probe:OT858 (+)probe:OT859 (+)probe:OT859
3.0Λ13 molecules 6.0Λ11 molecules 3.0Λ13 molecules 6.0Λ11 molecules gamma-actin gamma-actin G3PDH G3PDH
(+)probe:OT860 (+)probe:OT860 P2: OT1446 P2: OT1446
3.0Λ13 molecules 6.0Λ11 molecules 3.0Λ13 molecules 6.0Λ11 molecules
G3PDH G3PDH G3PDH G3PDH
P2: OT1447 P2: OT1447 P2: OT1448 P2: OT1448
3.0Λ13 molecules 6.0Λ11 molecules 3.0Λ13 molecules 6.0Λ11 molecules
Factor V Factor V
P1 : OT1915 P1 : OT1915
Figure imgf000011_0001
3.0A13 molecules 6.0Λ11 molecules
The probe array filter was washed two times in 3x SSC/1 % SDS for 7 minutes at room temperature. After the washes the damp filter was wrapped in foil and exposed to an X-ray film O/N at -70°C. The result of the exposure is shown in figure 3. The autoradiograph clearly shows a positive signal at the position of the G3PDH probe OT1446 on the array.
Example 5
In this example the Tyras reaction was used to generate 32P radiolabeled RNA from human poly A+ RNA template. The Tyras reaction contained 4 μl 5x NN* buffer (Tris- HCI 200 mM, pH 8.5, MgCI2 60 mM, KCL 350 mM, DTT 25 mM, dNTP's 5 mM each, rGTP 10mM, rUTP 10mM, rCTP 10mM), 4 μl primer mix PH26 (see example 2), 6.5 μl α-32P-ATP (reactions A and B) or 5.5 μl α-32P-ATP (reactions D, E and C) and 0.5 μl human poly A+ RNA (Clontech lot NR. 7050106, Cat.6518-1 ), in reaction C only water was added since this was the negative control. The ingredients were mixed by pipetting up and down 5 times and incubated at 65°C for 5 minutes and subsequently at 41°C for 5 minutes. Than 5 μl enzyme mix (sorbitol 1.5M, BSA 2.1 μg, RNase H 0.08 units, T7 RNA polymerase 32units and AMV-Reverse Transcriptase 25.3 units) was added to the reaction and gently mixed by tapping the tube. To reaction C, D and E 1μl of T7 mix (31 units T7 RNA polymerase and 0.6 units RNase H) was 10 added and gently mixed by tapping the tube. After a short incubation of 5 minutes 41 °C the tubes were briefly spun in centrifuge to collect all the droplets on the bottom of the tube. In all tubes 0.4 μl rATP (100 mM) was added. After the addition of the rATP the reactions A and B were incubated for 90 minutes at 41 °C and reaction C, D and E for 150 minutes at 41 °C. After the reaction the tubes were stored at -20°C. The reactions A, B and D were pooled and used to interrogate the "E quadrant" of an Atlas Human cDNA Expression Array (Clontech Laboratories, 1020 East Meadow Circle, Palo Alto, CA 94303-4230, USA, lot number 7090625). The filter with the "E quadrant" of an Atlas Human cDNA Expression Array was incubated in hybridization mix (see example 4) for 15 minutes at 50°C. The pooled reactions A, B and D were added to the hybridization mix on the filter and further incubated for 16 hours (O/N). After the hybridization the filter with "E quadrant" of an Atlas Human cDNA Expression Array was washed 4 times with 3x SSC/1 % SDS at room temperature. The damp filter was wrapped in foil and exposed to an X-ray film at -70°C for 65 hours. The result is depicted in figure 4 below and clearly shows positive spots on the array indicating good labeling of the poly A+ RNA with the Tyras method.
Example 6
In this example the addition of poly A polymerase to enhance the amplification of the Tyras reaction was investigated. The reaction consisted of model RNA containing not containing a poly A tail (see also example 1) +1 μg, ATP 1mM, tris 50 mM, pH=7.9, NaCI 250 mM, MgCI2 10 mM, BSA 2.5 mg/ml and poly A polymerase (Gibco BRL, catalogue number 18032-011) 1.3 units in a total volume of 30μl. The reactions were incubated at 37°C for 20 minutes (reaction A) or 60 minutes (reaction B). Subsequently the products of the reaction that now have a newly added poly A stretch to the 3' end were used in a Tyras reaction as described in example 2. After the 90-minute incubation at 41 °C the Tyras reaction products were analyzed on a 10% acrylamide Cleangei. For loading on the gel 0.5 μl of the Tyras reaction was mixed with 7.5 μl formamide loading dye (Ambion, 2130 woodward St. #200, Austin, Texas 78744-1832, USA) and run on the Cleangei according to the manufacturers protocol. The result is depicted in figure 5. Although many of the visible bands on the gel seem to be the result of ingredients in the reaction (see lane 3 and 4) at the position of the arrow a specific band can be observed in lanes 1 and 2. This result clearly indicates that it is possible to add a poly A stretch to RNA and subsequently use this newly added poly A stretch as start for the Tyras amplification.

Claims

11CLAIMS:
1. Method for creating, in a non specific manner, multiple RNA copies starting from nucleic acid containing starting material comprising a pool of mRNA's each mRNA comprising a poly-A tail wherein the material is simultaneously contacted with: an oligonucleotide comprising an oligo-dT sequence, the sequence of a promoter recognized by a RNA polymerase and a transcription initiation region which is located between the oligo-dT sequence and the sequence of the promoter, - an enzyme having reverse transcriptase activity an enzyme having RNase H activity and an enzyme having RNA polymerase activity, the necessary nucleotides and the resulting reaction mixture is maintained under the appropriate conditions for a sufficient amount of time for the enzymatic processes to take place.
2. Method according to claim 1 , wherein the oligonucleotide is blocked at its 3' end.
3. Method according to claim 1 or 2, wherein the promoter sequence is the T7- promoter sequence and the RNA polymerase is T7 RNA polymerase.
4. Method according to any of the preceding claims wherein the enzyme having reverse transcriptase activity is AMV-RT or MMLV-RT.
5. Method according to any of the preceding claims wherein (one of) the enzyme(s) having RNase H activity is E. coli RNase H.
6. Method according to claim 1 wherein the enzyme having RNase H activity is a reverse transcriptase.
7. Method according to claim 6 wherein the enzyme having RNase H activity is AMV-RT or MMLV-RT.
8. Method according to any of the preceding claims, wherein at least one of the nucleotides is provided with a label.
9. Method according to any of the preceding claims wherein the generated RNA is used as input material for further amplification.
10. Method according to claim 9 wherein the generated RNA copies made by the method described in claim 1 are contacted with a RNA ligase, 12 a double stranded nucleic acid complex comprising a double stranded DNA promoter sequence that can be recognized by a RNA polymerase, whereby one strand of said complex has a stretch of RNA attached to the 5' end of one of the DNA strands, an enzyme having RNA polymerase activity, the necessary nucleotides . and the resulting reaction mixture is maintained under the appropriate conditions for a sufficient amount of time for the enzymatic processes amplification to take place
11. Method according to claim 10, wherein the stretch of RNA attached to the 5' end of one of the DNA strands is phosphorylated at the 5' end
12. Method according to claim 10 or 11 , wherein the promoter sequence is the T7-promoter sequence and the RNA polymerase is T7 RNA polymerase.
13. Method according to claim 10, wherein at least one of the nucleotides is provided with a label.
14. Method according to claim 1 , wherein the reaction mixture further comprises an RNA ligase and a double stranded nucleic acid complex comprising a double stranded DNA promoter sequence that can be recognized by the RNA polymerase, whereby one strand of said complex has a stretch of RNA attached to the 5' end of one of the DNA strands.
15. Method according to claim 1 , wherein the generated RNA copies made by the method described in claim 1 are contacted with a poly A polymerase.
PCT/EP1999/000332 1998-02-27 1999-01-21 Method for the non-specific amplification of nucleic acid WO1999043850A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2000533589A JP3641206B2 (en) 1998-02-27 1999-01-21 Non-specific amplification method of nucleic acid
DE69900592T DE69900592T2 (en) 1998-02-27 1999-01-21 METHOD FOR THE SPECIFIC AMPLIFICATION OF A NUCLEIC ACID
AU25189/99A AU748847B2 (en) 1998-02-27 1999-01-21 Method for the non-specific amplification of nucleic acid
DK99904801T DK1056884T3 (en) 1998-02-27 1999-01-21 Method for Nonspecific Amplification of Nucleic Acid
AT99904801T ATE210736T1 (en) 1998-02-27 1999-01-21 METHOD FOR THE NON-SPECIFIC AMPLIFICATION OF A NUCLEIC ACID
CA002322073A CA2322073C (en) 1998-02-27 1999-01-21 Method for the non-specific amplification of nucleic acid
EP99904801A EP1056884B9 (en) 1998-02-27 1999-01-21 Method for the non-specific amplification of nucleic acid
US09/623,054 US6338954B1 (en) 1998-02-27 1999-01-21 Method for the non-specific amplification of nucleic acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98200619.9 1998-02-27
EP98200619 1998-02-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/623,054 A-371-Of-International US6338954B1 (en) 1998-02-27 1999-01-21 Method for the non-specific amplification of nucleic acid
US09/985,024 Division US20020061533A1 (en) 1998-02-27 2001-11-01 Method for the non-specific amplification of nucleic acid

Publications (1)

Publication Number Publication Date
WO1999043850A1 true WO1999043850A1 (en) 1999-09-02

Family

ID=8233425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/000332 WO1999043850A1 (en) 1998-02-27 1999-01-21 Method for the non-specific amplification of nucleic acid

Country Status (14)

Country Link
US (3) US6338954B1 (en)
EP (2) EP1170381A3 (en)
JP (1) JP3641206B2 (en)
KR (1) KR100440044B1 (en)
AT (1) ATE210736T1 (en)
AU (1) AU748847B2 (en)
CA (1) CA2322073C (en)
DE (1) DE69900592T2 (en)
DK (1) DK1056884T3 (en)
ES (1) ES2169943T3 (en)
ID (1) ID26107A (en)
PT (1) PT1056884E (en)
WO (1) WO1999043850A1 (en)
ZA (1) ZA99617B (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064959A1 (en) * 2000-03-02 2001-09-07 Akzo Nobel N.V. Detection of hepatitis b virus rna
US6582938B1 (en) * 2001-05-11 2003-06-24 Affymetrix, Inc. Amplification of nucleic acids
WO2004044239A1 (en) * 2002-10-30 2004-05-27 Pamgene B.V. Improved methods for generating multiple rna copies
US6794138B1 (en) * 1999-12-16 2004-09-21 Affymetrix, Inc. Methods of small sample amplification
FR2876116A1 (en) * 2004-10-01 2006-04-07 Biomerieux Sa METHOD FOR GENERATING TRANSCRIPTS
WO2006071776A2 (en) 2004-12-23 2006-07-06 Ge Healthcare Bio-Sciences Corp. Ligation-based rna amplification
EP1828422A2 (en) * 2004-11-15 2007-09-05 Bacterial Barcodes, Inc. Detection using primers to repetitive dna and transcription-based amplification thereby
US7727722B2 (en) 2001-08-29 2010-06-01 General Electric Company Ligation amplification
EP2280081A1 (en) * 2009-07-31 2011-02-02 Qiagen GmbH Method of normalized quantification of RNA
AU2012200749B2 (en) * 2004-12-23 2012-10-04 Global Life Sciences Solutions Usa Llc Ligation-based RNA amplification
CN101802222B (en) * 2006-08-14 2013-07-03 恰根有限公司 Method for synthesizing a cDNA in a sample in an enzymatic reaction
US8486628B2 (en) 2009-07-31 2013-07-16 Qiagen Gmbh Method of normalized quantification of nucleic acids using anchor oligonucleotides and adapter oligonucleotides
US9261460B2 (en) 2002-03-12 2016-02-16 Enzo Life Sciences, Inc. Real-time nucleic acid detection processes and compositions
US9353405B2 (en) 2002-03-12 2016-05-31 Enzo Life Sciences, Inc. Optimized real time nucleic acid detection processes

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166478B2 (en) * 2002-03-12 2007-01-23 Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US6852494B2 (en) 2003-01-10 2005-02-08 Linden Technologies, Inc. Nucleic acid amplification
US7494789B2 (en) 2003-05-09 2009-02-24 Genisphere Inc. Methods for amplification of nucleic acid sequences using staggered ligation
US20050153333A1 (en) * 2003-12-02 2005-07-14 Sooknanan Roy R. Selective terminal tagging of nucleic acids
US8802867B2 (en) 2004-04-01 2014-08-12 Genisphere, Llc Method for producing a sense RNA molecule
EP1863908B1 (en) 2005-04-01 2010-11-17 Qiagen GmbH Reverse transcription and amplification of rna with simultaneous degradation of dna
EP1762627A1 (en) 2005-09-09 2007-03-14 Qiagen GmbH Method for the activation of a nucleic acid for performing a polymerase reaction
WO2009021757A1 (en) * 2007-08-13 2009-02-19 Qiagen Gmbh Method for synthesizing a cdna in a sample in an enzymatic reaction
WO2009052214A2 (en) * 2007-10-15 2009-04-23 Complete Genomics, Inc. Sequence analysis using decorated nucleic acids
WO2009158119A2 (en) 2008-05-30 2009-12-30 Gen-Probe Incorporated Compositions, kits and related methods for the detection and/or monitoring of salmonella

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003552A1 (en) * 1989-08-28 1991-03-21 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression systems and vaccines
WO1992022663A1 (en) * 1991-06-14 1992-12-23 Life Technologies, Inc. Amplification of nucleic acid molecules
WO1993022461A1 (en) * 1992-05-06 1993-11-11 Gen-Probe Incorporated Nucleic acid sequence amplification method, composition and kit
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
WO1996002668A1 (en) * 1994-07-15 1996-02-01 Azco Nobel N.V. Use of rna polymerase to improve nucleic acid amplification process
FR2724934A1 (en) * 1994-09-26 1996-03-29 Bio Merieux Chimeric DNA-RNA oligo:nucleotide(s) for nucleic acid amplification
US5514545A (en) * 1992-06-11 1996-05-07 Trustees Of The University Of Pennsylvania Method for characterizing single cells based on RNA amplification for diagnostics and therapeutics
US5545522A (en) * 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
EP0731174A2 (en) * 1989-07-11 1996-09-11 Gen-Probe Incorporated Nucleic acid sequence amplification methods
WO1997027317A1 (en) * 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661450A (en) * 1983-05-03 1987-04-28 Molecular Genetics Research And Development Limited Partnership Molecular cloning of RNA using RNA ligase and synthetic oligonucleotides
US6114152A (en) * 1997-12-12 2000-09-05 The Regents Of The University Of California Methods for making nucleic acids

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0731174A2 (en) * 1989-07-11 1996-09-11 Gen-Probe Incorporated Nucleic acid sequence amplification methods
WO1991003552A1 (en) * 1989-08-28 1991-03-21 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression systems and vaccines
US5545522A (en) * 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
WO1992022663A1 (en) * 1991-06-14 1992-12-23 Life Technologies, Inc. Amplification of nucleic acid molecules
WO1993022461A1 (en) * 1992-05-06 1993-11-11 Gen-Probe Incorporated Nucleic acid sequence amplification method, composition and kit
US5514545A (en) * 1992-06-11 1996-05-07 Trustees Of The University Of Pennsylvania Method for characterizing single cells based on RNA amplification for diagnostics and therapeutics
WO1996002668A1 (en) * 1994-07-15 1996-02-01 Azco Nobel N.V. Use of rna polymerase to improve nucleic acid amplification process
FR2724934A1 (en) * 1994-09-26 1996-03-29 Bio Merieux Chimeric DNA-RNA oligo:nucleotide(s) for nucleic acid amplification
WO1997027317A1 (en) * 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIEVITS T ET AL: "NASBA TM ISOTHERMAL ENZYMATIC IN VITRO NUCLEIC ACID AMPLIFICATION OPTIMIZED FOR THE DIAGNOSIS OF HIV-1 INFECTION", JOURNAL OF VIROLOGICAL METHODS, vol. 35, no. 3, 1 December 1991 (1991-12-01), pages 273 - 286, XP000576430 *
ROMANO J W ET AL: "NASBA A NOVEL, ISOTHERMAL DETECTION TECHNOLOGY FOR QUALITATIVE AND QUANTITATIVE HIV-1 RNA MEASUREMENTS", CLINICS IN LABORATORY MEDICINE, vol. 16, no. 1, 1 March 1996 (1996-03-01), pages 89 - 103, XP000600141 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794138B1 (en) * 1999-12-16 2004-09-21 Affymetrix, Inc. Methods of small sample amplification
WO2001064959A1 (en) * 2000-03-02 2001-09-07 Akzo Nobel N.V. Detection of hepatitis b virus rna
US6582938B1 (en) * 2001-05-11 2003-06-24 Affymetrix, Inc. Amplification of nucleic acids
US7727722B2 (en) 2001-08-29 2010-06-01 General Electric Company Ligation amplification
US10144956B2 (en) 2002-03-12 2018-12-04 Enzo Biochem, Inc. Processes for quantitative or qualitative detection of single-stranded or double-stranded nucleic acids
US10144957B2 (en) 2002-03-12 2018-12-04 Enzo Life Sciences, Inc. Optimized real time nucleic acid detection processes
US9353405B2 (en) 2002-03-12 2016-05-31 Enzo Life Sciences, Inc. Optimized real time nucleic acid detection processes
US9316587B2 (en) 2002-03-12 2016-04-19 Enzo Life Sciences, Inc. Processes for quantitative or qualitative detection of single-stranded or double-stranded nucleic acids
US9261460B2 (en) 2002-03-12 2016-02-16 Enzo Life Sciences, Inc. Real-time nucleic acid detection processes and compositions
WO2004044239A1 (en) * 2002-10-30 2004-05-27 Pamgene B.V. Improved methods for generating multiple rna copies
WO2006054003A1 (en) * 2004-10-01 2006-05-26 Biomerieux Method for generating transcripts
FR2876116A1 (en) * 2004-10-01 2006-04-07 Biomerieux Sa METHOD FOR GENERATING TRANSCRIPTS
EP1828422A4 (en) * 2004-11-15 2008-07-30 Bacterial Barcodes Inc Detection using primers to repetitive dna and transcription-based amplification thereby
EP1828422A2 (en) * 2004-11-15 2007-09-05 Bacterial Barcodes, Inc. Detection using primers to repetitive dna and transcription-based amplification thereby
AU2012200749B2 (en) * 2004-12-23 2012-10-04 Global Life Sciences Solutions Usa Llc Ligation-based RNA amplification
WO2006071776A3 (en) * 2004-12-23 2006-09-14 Ge Healthcare Bio Sciences Ligation-based rna amplification
WO2006071776A2 (en) 2004-12-23 2006-07-06 Ge Healthcare Bio-Sciences Corp. Ligation-based rna amplification
CN101802222B (en) * 2006-08-14 2013-07-03 恰根有限公司 Method for synthesizing a cDNA in a sample in an enzymatic reaction
US9217173B2 (en) 2006-08-14 2015-12-22 Qiagen Gmbh Method of polyadenylation and CDNA synthesis in a single reaction
EP2280081A1 (en) * 2009-07-31 2011-02-02 Qiagen GmbH Method of normalized quantification of RNA
WO2011012329A1 (en) * 2009-07-31 2011-02-03 Qiagen Gmbh Method of normalized quantification of rna
US8486628B2 (en) 2009-07-31 2013-07-16 Qiagen Gmbh Method of normalized quantification of nucleic acids using anchor oligonucleotides and adapter oligonucleotides

Also Published As

Publication number Publication date
EP1056884B9 (en) 2002-07-24
DE69900592T2 (en) 2002-08-22
US20020061533A1 (en) 2002-05-23
DE69900592D1 (en) 2002-01-24
KR100440044B1 (en) 2004-07-14
PT1056884E (en) 2002-06-28
ZA99617B (en) 1999-07-27
US20030113875A1 (en) 2003-06-19
US6338954B1 (en) 2002-01-15
EP1056884A1 (en) 2000-12-06
AU2518999A (en) 1999-09-15
KR20010041371A (en) 2001-05-15
CA2322073C (en) 2003-12-23
ES2169943T3 (en) 2002-07-16
JP2002505087A (en) 2002-02-19
DK1056884T3 (en) 2002-02-25
EP1056884B1 (en) 2001-12-12
EP1170381A2 (en) 2002-01-09
CA2322073A1 (en) 1999-09-02
ID26107A (en) 2000-11-23
ATE210736T1 (en) 2001-12-15
EP1170381A3 (en) 2004-01-28
JP3641206B2 (en) 2005-04-20
AU748847B2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
EP1056884B9 (en) Method for the non-specific amplification of nucleic acid
US5580726A (en) Method and Kit for enhanced differential display
US5262311A (en) Methods to clone polyA mRNA
EP0914470B1 (en) Subtractive amplification
US5554517A (en) Nucleic acid amplification process
EP0310229A1 (en) Selective amplification of target polynucleotide sequences
US7083926B2 (en) Method for identifying accessible binding sites on RNA
JPH07500735A (en) Messenger RNA identification, isolation and cloning
WO2001079549A2 (en) CONSTRUCTION OF UNI-DIRECTIONALLY CLONED cDNA LIBRARIES FROM MESSENGER RNA FOR IMPROVED 3'END DNA SEQUENCING
EP1682676B1 (en) Method for amplification of rna sequences
Yoshikawa et al. Differential display with carboxy-X-rhodamine-labeled primers and the selection of differentially amplified cDNA fragments without cloning
US6706476B1 (en) Process for amplifying and labeling single stranded cDNA by 5′ ligated adaptor mediated amplification
WO2005079357A9 (en) Nucleic acid representations utilizing type iib restriction endonuclease cleavage products
US6498025B1 (en) Methods and compositions for cDNA synthesis
CA2073184A1 (en) Compositions and methods for analyzing genomic variation
WO2002092774A2 (en) Replicase cycling reaction amplification
Dominguez et al. Cloning of ARE-containing genes by AU-motif-directed display
WO2000020629A2 (en) Quantitation of rna
WO1995035369A9 (en) METHODS AND COMPOSITIONS FOR cDNA SYNTHESIS
Shen et al. Analysis of selective gene activation in yeast by differential display
JP2004147503A (en) Method for detecting nucleic acid with high sensitivity
RICOTE et al. Chapter XXVII
Price Subfamilies defined by the 5'ends of long interspersed repetitive elements in rabbit DNA, and regulatory elements upstream of the rabbit varepsilon-globin gene
AU1832301A (en) Methods and compositions for cDNA synthesis
JP2004147501A (en) Method for detecting dna with high sensitivity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA ID JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999904801

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09623054

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2322073

Country of ref document: CA

Ref country code: CA

Ref document number: 2322073

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020007009493

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 25189/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999904801

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007009493

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1999904801

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 25189/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020007009493

Country of ref document: KR